Quantified Bone Scan Response After Radium-223

ASCO 2014 - A Randomized, Open-Label Phase 2a Study Evaluating Quantified Bone Scan Response Following Treatment with Radium-223 Dichloride Alone or in Combination with Abiraterone Acetate or Enzalutamide in Patients with Castration-Resistant Prostate Cancer who have Bone Metastases

Daniel Petrylak, MD discusses a study designed to explore the utility of bone scan imaging to assess treatment response to radium-223.

Daniel Petrylak, MD
Yale Cancer Center

Click HERE to view the poster from this session